FDG PET and PET/CT Imaging in Lymphoma and Melanoma
- 1 July 2004
- journal article
- review article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 10 (4) , 262-270
- https://doi.org/10.1097/00130404-200407000-00007
Abstract
FDG PET imaging is rapidly gaining acceptance in numerous clinical applications in oncology. PET/CT is a new imaging tool, which takes advantage of the excellent anatomic resolution of CT and the biologic characterization provided by FDG PET which together results in improvement in accuracy of detecting the extent of disease, provide a guide to biopsy or surgery, allow early response evaluation and prognostication. This article will provide specific clinical applications for the utilization of these imaging modalities in both lymphoma and melanoma.Keywords
This publication has 18 references indexed in Scilit:
- FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients withde novoHodgkin Lymphoma: A Blinded ComparisonLeukemia & Lymphoma, 2004
- Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphomaThe American Journal of Medicine, 2002
- Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission TomographyJournal of Clinical Oncology, 2002
- Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphomaBritish Journal of Haematology, 2001
- Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatmentRadiography, 1999
- Positron emission tomography in patients with primary CNS lymphomas.Journal of Neuro-Oncology, 1999
- Positron Emission Tomography with 18-Fluorodeoxyglucose in the Staging and Follow-up of Lymphoma in the ChestActa Oncologica, 1999
- Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphomaNuclear Medicine Communications, 1998
- Staging Hodgkin's Disease with 18-FDG PET Comparison with CT and SurgeryClinical Positron Imaging, 1998
- Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.Radiology, 1994